PD
TGTX icon

Point72 (DIFC)’s TG Therapeutics TGTX Stock Holding History

Point72 (DIFC)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$107K Sell
2,968
-466
-14% -$15.3K 0.01% 566
2025
Q2 		$124K Buy
+3,434
New +$128K ﹤0.01% 888
2024
Q2 		– Sell
-15,771
Closed -$240K – 1897
2024
Q1 		$240K Buy
+15,771
New +$251K 0.01% 917

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 (DIFC)'s TGTX Position: Q3 2025 in Review

Point72 (DIFC) reduced its TG Therapeutics (TGTX) stake by 14% in Q3 2025, selling an estimated $15.3K and leaving 2,968 shares worth $107K. The position accounts for 0.01% of the portfolio, ranked #566.

Point72 (DIFC) first reported a position in TGTX in Q1 2024 and has held it in 3 quarters since. The position peaked at $240K in Q1 2024. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Point72 (DIFC) held 2,968 shares of TG Therapeutics worth $107K as of Q3 2025.
  • Point72 (DIFC) sold 466 TG Therapeutics shares in Q3 2025, an estimated $15.3K.
  • TG Therapeutics made up 0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #566 holding.
  • Point72 (DIFC) first reported a position in TG Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Point72 (DIFC)'s TG Therapeutics position peaked at $240K in Q1 2024.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.